Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new biopsy needle collect better tissue samples?

NCT ID NCT07800013

Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This trial compares two types of disposable needles used in CT-guided biopsies, a procedure that takes a small tissue sample from a suspicious area deep in the body. Researchers want to see whether a newer full-core needle collects longer, heavier, and less fragmented samples than the standard side-notch needle. The study includes 40 adults aged 18 to 80 who need a biopsy for a deep lesion at least 4 cm in size. Participants are randomly assigned to one needle type, and researchers measure sample quality right after the biopsy and check for complications 7 days later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Merit Medical CorVocet full-core disposable biopsy needle compared with Bard side-notch disposable biopsy needle
What this could lead to
If the full-core needle collects larger, more intact tissue samples, it could improve diagnostic accuracy for people needing biopsies.
What could go wrong
This is a small, early-stage study with 40 participants, so results may not apply broadly. The new needle might not outperform the standard one, and any biopsy carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Jul 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Age: 18-80 years old \- Imaging suggests deep organ space-occupying lesion, requiring biopsy to confirm its nature \- Coagulation function is basically normal (INR≤1.5) \- Lesion short diameter ≥4cm \- Signed informed consent form. Exclusion Criteria: \- Patients with coagulopathy who have not discontinued anticoagulant therapy \- Patients with severe infections or pregnancy \- Patients who, in the investigator's judgment, are not suitable for enrollment or have a high risk of puncture.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOPSY

Contacts and locations

Locations

  • West China hospital

    Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.